1. 106188341 肝素钠下脚料制备高纯度硫酸皮肤素工艺
CN
07.12.2016
C08B 37/08 Loading...
C08B 37/08
Loading...
102016000597994
河北常山生化药业股份有限公司
赵焕荣
C08B 37/08
Loading...
本发明涉及一种利用肝素钠下脚料制备高纯度硫酸皮肤素的方法，它是以生产精品肝素钠产出的下脚料为原料，通过乙醇分级沉淀，得到类肝素粗品和硫酸皮肤素粗品，然后类肝素粗品通过乙醇分级沉淀、双氧水进行氧化，得到正比旋类肝素和负比旋类肝素；硫酸皮肤素粗品通过亚硝酸盐降解，使粗品中含有的肝素类物质降解成低分子肝素类物质，再通过乙醇分级沉淀、双氧水氧化得到纯度达98%以上的硫酸皮肤素。解决了长期以来市场上存在的硫酸皮肤素纯度不高的问题，实现了将下脚料变废为宝过程，可以为企业创造出较大的额外收益，其工艺步骤简易，工艺过程绿色环保，不产生有毒有害物质，成本低廉，易于规模化生产。
2. 106146688 肝素钠下脚料制备类肝素工艺
CN
23.11.2016
C08B 37/10 Loading...
C08B 37/10
Loading...
102016000598231
河北常山生化药业股份有限公司
田志鹏
C08B 37/10
Loading...
本发明公开了一种利用肝素钠下脚料制备类肝素工艺，它是以生产精品肝素钠产出的下脚料为原料，通过乙醇分级沉淀，得到类肝素粗品，然后类肝素粗品通过乙醇分级沉淀、双氧水进行氧化，得到正比旋类肝素和负比旋类肝素，使粗品中含有的肝素类物质降解成低分子肝素类物质。本发明解决了长期以来市场上存在的硫酸皮肤素纯度不高的问题，制得高纯度硫酸皮肤素可为舒洛地特提供原料同时该物质具有抗血栓、抗水肿、滋润皮肤等作用，使下脚料变废为宝，创造额外价值，制得的类肝素具有抗血栓、消炎、止痛等作用。工艺步骤简易，绿色环保，不产生有毒有害物质，成本低廉，易于规模化生产。
3. 103724457 Method for removing impurities in coarse heparin product by using ceramic membrane
CN
16.04.2014
C08B 37/10 Loading...
C08B 37/10
Loading...
201310707165.8
河北常山生化药业股份有限公司
姬胜利
C08B 37/10
Loading...
The invention discloses a method for removing impurities in a coarse heparin product by using a ceramic membrane. The method comprises the following steps: mixing intestinal mucosa with water and then adding NaCl and protease to carry out enzymolysis; filtering by a ceramic membrane after filtering enzymatic hydrolysate; eluting exchange resin after carrying out ion exchange on the clear liquor; and adding ethanol to eluent and then standing, participating, dewatering and drying, so as to obtain the coarse heparin product. By adopting a dynamic cross flow filtration mode, the enzymatic hydrolysate flows at a high speed on the surface of an inside membrane of a ceramic membrane tube at a certain flow rate; and enabling the enzymatic hydrolysate to penetrate a microporous membrane along the direction vertical to the ceramic membrane, intercepting macromolecular proteins by the membrane, so that the enzymatic hydrolysate and the impurities are separated and purified. The method is high in separation accuracy, and high in filtering efficiency, the yield of the product can be up to 99.5%, and the enzymatic hydrolysate has the advantages of being clear, lower in impurity content, free of heparin loss, convenient and fast for later adsorption and the like. The impurities in the extraction process of the coarse heparin product can be furthest removed under the condition that the heparin is not lost, the quality and the yield of the product are ensured, and the method is reasonable in production cost and applicable to large-scale industrial production.
4. 103342761 一种膜分离制备依诺肝素钠工艺
CN
09.10.2013
C08B 37/10 Loading...
C08B 37/10
Loading...
201310295978.0
河北常山生化药业股份有限公司
姬胜利
C08B 37/10
Loading...
本发明公开了一种膜分离技术制备依诺肝素钠工艺。肝素钠依次经过季铵盐盐化、苄基酯化、碱性降解等处理实现β-降解、氧化脱色、过滤除杂、滤液再经超滤处理，得到平均分子量及分子量分布范围符合要求的依诺肝素钠产品。本发明采用不同孔径的膜超滤实现控制产物的分子量和分子量分布，制备出高纯度、高活性的依诺肝素钠产品。本发明采取双氧水氧化脱色和活性炭过滤除杂，有效去除了反应体系中的杂质并且显著改善了产品色度。本发明制备的依诺肝素钠重均分子量为3800～5000，分子量大小和分布范围均比较理想，测得的抗FⅩa/抗FⅡa比值大于3.3，导致出血危险的主要因素抗FⅡa活性大幅降低，发挥抗栓作用的抗FⅩa活性相对提高，产品的有效性和安全性优势明显。
5. 102050888 Method for preparing enoxaparin sodium
CN
11.05.2011
C08B 37/10 Loading...
C08B 37/10
Loading...
201010583647.3
Hebei Changshan Biochemical Pharmaceutical Co., Ltd.
Gao Shuhua
C08B 37/10
Loading...
The invention discloses a method for preparing enoxaparin sodium, comprising the steps of salinizing, drying, esterfying, alcohol precipitating, oxidizing, alcohol precipitating, fine filtering and freeze drying. In the method provided by the invention, a hydrophilic liquid phase reaction, a hydrophobic liquid phase reaction and a solid phase reaction are adopted, so that macromolecule sodium heparin is degraded into micromolecule sodium heparin with a specific structure, and the molecular weights of products and molecular weight distribution ranges are controlled, thus anti-FIIa activity resulting in bleeding risk is greatly reduced, the anti-FXa activity is relatively improved, and the product effectiveness and safety advantages are obvious. The enoxaparin sodium can be used for effectively preventing venous thromboembolism and pulmonary embolism, can be used for thrombosis before and after operations of orthopedic surgery and neurosurgery, and can be used for greatly reducing apoplexy risk, more effectively reducing death, cardiac failure and recurrent angina of patients suffering from unstable coronary artery syndromes, reducing hypertriglyceridemia and effectively eliminating the side effects of haemorrhage, osteoporosis and induced thrombocytopenia after long-term use of common unfractionated heparin sodium and derivates of common unfractionated heparin sodium.

